BAP1 and Miyoshi myopathy: in the PrE0505 trial, testing the efficacy of durvalumab plus chemotherapy in MM first line setting, demonstrated that BAP1 germline mutations were associated with a significantly prolonged survival after chemo-immunotherapy.